APOBEC Enzymes as Targets for Virus and Cancer Therapy
- 1 January 2018
- journal article
- review article
- Published by Elsevier in Cell Chemical Biology
- Vol. 25 (1) , 36-49
Abstract
No abstract availableKeywords
Funding Information
- NIH (R01-GM110129, R01-GM118000, R37-AI064046, R21-CA206309, F31-CA183246)
This publication has 134 references indexed in Scilit:
- APOBEC3B is an enzymatic source of mutation in breast cancerNature, 2013
- Preclinical In Vivo Evaluation of the Safety of a Multi-shRNA-based Gene Therapy Against HIV-1Molecular Therapy Nucleic Acids, 2013
- Mutational Processes Molding the Genomes of 21 Breast CancersCell, 2012
- First-In-Class Small Molecule Inhibitors of the Single-Strand DNA Cytosine Deaminase APOBEC3GACS Chemical Biology, 2011
- Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiationJournal of Cellular Biochemistry, 2011
- Multifaceted Counter-APOBEC3G Mechanisms Employed by HIV-1 VifJournal of Molecular Biology, 2011
- Determinants of sequence-specificity within human AID and APOBEC3GDNA Repair, 2010
- Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeuticsExpert Reviews in Molecular Medicine, 2010
- Multiple ways of targeting APOBEC3–virion infectivity factor interactions for anti-HIV-1 drug developmentTrends in Pharmacological Sciences, 2009
- Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcriptsNature, 2003